Patents Examined by S. Devi
  • Patent number: 10519430
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 31, 2019
    Assignee: Alimentary Health Ltd.
    Inventors: Jose Carlos Garcia-Garcia, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony
  • Patent number: 10124051
    Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group in the capsular polysaccharide, to give an oxidized polysaccharide with an aldehyde group; and (b) coupling the oxidized polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: November 13, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
  • Patent number: 10067147
    Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: September 4, 2018
    Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), Conicet (Consejo Nacional de Investigaciones Cientificas y Tecnicas, Institut Jean Paoli & Irene Calmettes, Universite d'Aix-Marseille, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Juan Iovanna, Virginia Pasquinelli, Maria Madgalena Gherardi, Hector Eduardo Chuluyan, Ana Inès Rovetta, Delfina Pena, Véronica Edith Garcia
  • Patent number: 10064932
    Abstract: The invention provides a method for immunizing a patient, comprising administering multiple conjugates meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a diphtheria toxoid (or derivative thereof).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 4, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cameron John Marshall
  • Patent number: 10046042
    Abstract: The present invention provides a meningococcal conjugate vaccine for groups A, C, Y and W135, which is a tetravalent conjugate vaccine comprising polysaccharide-protein conjugates obtained by respectively conjugating a capsular polysaccharide of Neisseria meningitides groups A, C, Y and W135 to a outer membrane vesicle protein selected from a group consisting of Neisseria meningitides group B serotypes 4 and 15 outer membrane vesicle proteins.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 14, 2018
    Assignee: Beijing Sanroad Biological Products Co., Ltd.
    Inventor: Wang Jianhua
  • Patent number: 10048263
    Abstract: The method of the invention allows confirmation of infections caused by Streptococcus agalactiae bacterial species. The method employs a specific reaction of immunoreactive proteins obtained from clinical isolates of Streptococcus agalactiae with antibodies present in the serum of patients.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 14, 2018
    Assignees: Uniwersytet Jagiellonski, Instytut Immunologii I Terapii Doswiadczainej Im. Ludwika Hirszfelds Pan
    Inventors: Monika Brzychczy-Wloch, Sabina Górska, Ewa Brzozowska, Andrzej Gamian, Piotr Heczko
  • Patent number: 10046043
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 14, 2018
    Assignee: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Patent number: 9981031
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 29, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Paolo Costantino
  • Patent number: 9981026
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: May 29, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Patent number: 9977020
    Abstract: Chimera proteins including: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: May 22, 2018
    Assignee: BIOMERIEUX
    Inventors: Lionel Levet, Odile Mejan-Letourneur
  • Patent number: 9976149
    Abstract: A Listeria bacterium is disclosed which comprises a first mutation in the multidrug resistance transporter M (MdrM) gene which causes a decrease in interferon-? production in macrophages as compared to wild-type Listeria bacterium and a second mutation in the multidrug resistance transporter T (MdrT) gene which causes a decrease in interferon-? production in macrophages as compared to the wild-type Listeria bacterium.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: May 22, 2018
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Anat Afriat Herskovits, Millie Kaplan Zeevi
  • Patent number: 9950028
    Abstract: The present invention relates to a method for preventing or treating virus and protozoa infection in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (SBP)-tagged immunostimulatory protein and a SBP-binding matrix, wherein the immunostimulatory protein is from Ganoderma species. The present invention also relates to a method for inducing interferon-gamma production in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (SBP)-tagged immunostimulatory protein and a SBP-binding matrix, wherein the immunostimulatory protein is from Ganoderma species.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: April 24, 2018
    Assignee: SIMPSON BIOTECH CO., LTD
    Inventors: Chia-Chin Sheu, Chang-Yeu Liu
  • Patent number: 9950052
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: April 24, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Patent number: 9950041
    Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: April 24, 2018
    Inventors: Karl Edwin Griswold, Thomas Carr Scanlon
  • Patent number: 9943581
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: April 17, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Patent number: 9943582
    Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: April 17, 2018
    Assignee: Boise State University
    Inventor: Juliette Tinker
  • Patent number: 9931363
    Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: April 3, 2018
    Assignee: PROBIOTICAL S.p.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna, Lorenzo Drago
  • Patent number: 9932373
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: April 3, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Lisa L. Herron-Olson, Drew M. Catron
  • Patent number: 9931397
    Abstract: The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 1:2-1:5, and wherein at least one different capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 5:1-1:1.99.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: April 3, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • Patent number: 9925253
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such as E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: March 27, 2018
    Assignee: EPITOPIX, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling